ScreenerHero

BOLTBolt Biotherapeutics, Inc.

NAS · US · Healthcare · Biotechnology · boltbio.com
3.665USD+12.42%Mkt Cap: 7.06M $P/E: —

Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies for the treatment of cancer. The company's pipeline products include BDC-4182, a next-generation Boltbody ISAC that t…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap7.06M $
Enterprise Value10.19M $
Revenue (TTM)4.70M $
Gross Profit-16.80M $
Net Income (TTM)-33.38M $
Revenue/Share2.680 USD
Last Price3.665 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees23
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS0977021049
Valuation
P/E (Trailing)—
P/E (Forward)-0.16
PEG—
EV/EBITDA-0.37
EV/Revenue2.17
P/S1.31
P/B0.49
EPS (TTM)-15.97
EPS (Forward)-20.19
52W Range
3.13013% of range7.200
52W High7.200 USD
52W Low3.130 USD
Profitability
Gross Margin0.00%
Oper. Margin-151320.00%
EBITDA Margin0.00%
Profit Margin-433.74%
ROE-125.92%
ROA-58.81%
Growth
Revenue Growth-99.70%
Earnings Growth—
Cash Flow & Leverage
Operating CF-39.85M $
CapEx (TTM)72.00K $
FCF Margin-399.83%
FCF Yield-266.17%
Net Debt4.03M $
Net Debt/EBITDA-0.15
Balance Sheet
Debt/Equity0.87
Current Ratio2.61
Quick Ratio2.24
Book Value/Sh6.562 USD
Cash/Share9.135 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:20
Split DateJun 9, 2025
Analyst Consensus
Rating2.0 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)29.00 USD
Upside (mean)+691.3%
Target Range5.000 USD – 75.00 USD
$5.000+691.3% to mean$75.00
# Analysts3
Ownership
Shares Out.1.93M
Float1.68M
Insiders3.46%
Institutions27.92%
Short Interest
Short Ratio0.3d
Short % Float0.20%
Short % Out.0.20%
Shares Short3.75K
Short (prev mo.)16.70K
Technical
SMA 503.974 (-7.8%)
SMA 2004.791 (-23.5%)
Beta1.08
S&P 52W Chg18.16%
Avg Vol (30d)23.13K
Avg Vol (10d)35.77K
Technical Indicators
RSI (14)46.6
MACD-0.1927
MACD Signal-0.1553
MACD Hist.-0.0373
BB Upper4.354 USD
BB Middle3.763 USD
BB Lower3.173 USD
BB Width31.38%
ATR (14)0.2927 USD
Vol Ratio (20d)2.74x